You can’t tell the players without a scorecard, especially in biopharma. This week alone, AstraZeneca reportedly turned down a £60 billion ($101 billion) offer from Pfizer, while Novartis, GlaxoSmithKline, and Eli Lilly agreed to overhaul themselves in a series of deals totaling $28.5 billion. Also, Valeant Pharmaceuticals International made a hostile $45.7 billion bid for Botox maker Allergan supported by Allergan’s largest shareholder, investor William Ackman’s Pershing Square Capital Management.

Poll Question:
What company not in this week’s M&A headlines do you think will be at the center of a megamerger, acquisition, or partial selloff this year?

Bristol-Myers Squibb
22

Johnson & Johnson
19

Merck & Co.
29

Roche
18

Sanofi
16

Another company
22